Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ABT-494 monotherapy versus methotrexate in methotrexate-naive rheumatoid arthritis
NL-OMON43652Phase 3Withdrawn
- Sponsor
- AbbVie Inc.
- Start
- Nov 2015
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of upadacitinib and methotrexate in rheumatoid arthritis (RA) (3 arms), sponsored by AbbVie Inc. Primary endpoints: ACR50 response at Week 24, Clinical remission at Week 24 and 2 more. Planned start Nov 2015; status: withdrawn.
02
Drugs
upadacitinibmethotrexate
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on NL-OMON43652.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON43652.